Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 9:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Efinopegdutide in Participants With Hepatic Impairment (MK-6024-014)

NCT06052566
Conditions
Non-alcoholic Steatohepatitis, Hepatic Impairment
Interventions
Efinopegdutide
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
4
States / cities
Miami, Florida • Tampa, Florida • San Antonio, Texas
Conditions
Non Alcoholic Fatty Liver
Interventions
Omega-3, Olive oil
Dietary Supplement
Lead sponsor
Pronova BioPharma
Industry
Eligibility
18 Years and older
Enrollment
172 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
7
States / cities
Hialeah, Florida • Lake Worth, Florida • Lauderdale Lakes, Florida + 3 more
Conditions
Nonalcoholic Steatohepatitis
Interventions
pioglitazone-placebo, pioglitazone, Vitamin E, Vitamin E-placebo
Drug · Dietary Supplement
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
2
States / cities
Gainesville, Florida • San Antonio, Texas
Completed Phase 1Phase 2 Interventional Results available

Spironolactone Therapy In Young Women With NASH

NCT03576755
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
Spironolactone 100mg, Placebo oral capsule
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
San Francisco, California
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Study of HU6 in Healthy Volunteers

NCT04463017
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
HU6
Drug
Lead sponsor
Rivus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Saint Paul, Minnesota
Conditions
Nonalcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
37
States / cities
Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 33 more
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
MRI-PDFF
Other
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Timeline
2022 – 2023
U.S. locations
9
States / cities
Chandler, Arizona • Tucson, Arizona • Panorama City, California + 6 more
Conditions
NASH
Interventions
Pegozafermin, Placebo
Drug · Other
Lead sponsor
89bio, Inc.
Industry
Eligibility
21 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Madison, Alabama • Chandler, Arizona • Tucson, Arizona + 21 more
Conditions
Nonalcoholic Steatohapatitis
Interventions
Roflumilast, Pioglitazone, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Coronado, California • Annapolis, Maryland • Baltimore, Maryland
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Tolerability Study of SHP626 in Overweight and Obese Adults

NCT02287779
Conditions
Non-Alcoholic Steatohepatitis
Interventions
SHP626, Placebo
Drug
Lead sponsor
Mirum Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Knoxville, Tennessee
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
VK2809, Placebos
Drug
Lead sponsor
Viking Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
68
States / cities
Madison, Alabama • Glendale, Arizona • Tucson, Arizona + 57 more
Conditions
Non-alcoholic Fatty Liver Disease
Interventions
Efimosfermin Alfa, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
52
States / cities
Arcadia, California • Covina, California • Los Angeles, California + 41 more
Conditions
NAFLD
Interventions
RYI-018, Placebo
Biological
Lead sponsor
Bird Rock Bio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
4
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida + 1 more
Completed Phase 2 Interventional Results available

Anti-LPS Antibody Treatment for Pediatric NAFLD

NCT03042767
Conditions
Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions
IMM-124E, Placebo
Biological · Other
Lead sponsor
Miriam Vos, MD
Other
Eligibility
6 Years to 19 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
NAFLD, Fatty Liver, Obesity, Metabolic Syndrome
Interventions
Diet Intervention
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
11 Years to 17 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASH) / Nonalcoholic Steatohepatitis (NASH) With Fibrosis
Interventions
Pegozafermin, Placebo
Biological · Other
Lead sponsor
89bio, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
154
States / cities
Birmingham, Alabama • Chandler, Arizona • Flagstaff, Arizona + 132 more
Conditions
Nonalcoholic Steatohepatitis, Fibrosis
Interventions
Saroglitazar Magnesium 2 mg, Saroglitazar Magnesium 4 mg, Placebo
Drug
Lead sponsor
Zydus Therapeutics Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
101
States / cities
Birmingham, Alabama • Homewood, Alabama • Phoenix, Arizona + 75 more
Completed Not applicable Interventional Results available

Dietary Treatment Study of Pediatric NAFLD

NCT02513121
Conditions
Nonalcoholic Fatty Liver Disease
Interventions
Dietary modification
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
11 Years to 16 Years · Male only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
San Diego, California • Atlanta, Georgia
Conditions
Fatty Liver
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Liver Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years and older
Enrollment
2,501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2020
U.S. locations
8
States / cities
La Jolla, California • San Francisco, California • Indianapolis, Indiana + 5 more
Completed No phase listed Observational

NAFLD Pediatric Database 2

NCT01061684
Conditions
Liver Disease
Interventions
Not listed
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
2 Years to 17 Years
Enrollment
969 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2020
U.S. locations
12
States / cities
San Diego, California • San Francisco, California • Atlanta, Georgia + 9 more
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
IMM-124E, Placebo
Biological · Other
Lead sponsor
Immuron Ltd.
Industry
Eligibility
18 Years to 99 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
17
States / cities
Chula Vista, California • San Diego, California • San Francisco, California + 12 more
Conditions
NASH - Nonalcoholic Steatohepatitis
Interventions
TERN-501, TERN-101, Placebo
Drug · Other
Lead sponsor
Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
162 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
35
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 26 more
Conditions
Non Alcoholic Steatohepatitis (NASH)
Interventions
Obeticholic Acid, Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,477 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
175
States / cities
Birmingham, Alabama • Dothan, Alabama • Chandler, Arizona + 116 more